Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

Phase 3

Completed

• Conditions: Colorectal Cancer

• Registration Number: NCT00005979
• Lead Sponsor: UNICANCER

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without irinotecan in treating colon cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without irinotecan in treating patients who have stage III colon cancer.

Detailed Description

OBJECTIVES:

* Compare the effect of leucovorin calcium and fluorouracil with or without irinotecan on the 3 year survival rate and overall survival of patients with resected node positive colon cancer at high risk of recurrence.

* Compare toxicities of these regimens in these patients.

* Compare quality of life of these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, disease type (occlusion vs perforation vs N2 only), delay between surgery and chemotherapy (28 days or less vs over 28 days), and age (under 65 vs 65 and over). Patients are randomized to one of two treatment arms.

* Arm I: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2.

* Arm II: Patients receive irinotecan IV over 90 minutes on day 1 followed by leucovorin calcium and fluorouracil as in arm I.

Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed before treatment, after 6 and 12 courses, and then at 1 year.

Patients are followed every 3 months for 2 years, then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 400 patients (200 per arm) will be accrued for this study within 3 years.

Study Timeline

• Study Start: 1998-07-22
• Study First Submitted: 2000-07-05
• Study First Submitted QC: 2003-01-26
• Study First Posted: 2003-01-27
• Primary Completion: 2005-09-26
• Study Completion: 2007-09-01
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-15
• Last Update Posted: 2021-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (30)

Centre Paul Papin; 🇫🇷 Angers, France

Clinique St. Etienne; 🇫🇷 Bayonne, France

Institut Bergonie; 🇫🇷 Bordeaux, France

Centre Hospitalier de Fleyriat; 🇫🇷 Bourg-En-Bresse, France

Centre Hospitalier de Bourgoin - Jallieu; 🇫🇷 Bourgoin-Jallieu, France

Centre Hospitalier General; 🇫🇷 Brive, France

Centre Regional Francois Baclesse; 🇫🇷 Caen, France

Centre Hospitalier Universitaire Henri Mondor; 🇫🇷 Creteil, France

Faculte de Medecine; 🇫🇷 Dijon, France

Hopital Du Bocage; 🇫🇷 Dijon, France

Scroll for more (20 remaining)